ReviewCell reports methods2024
Mimicking and analyzing the tumor microenvironment.
Review in Cell reports methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- TIMEL: Deep learning-statistical integration reveals spatial stromal and immune signatures of aggressive colon cancer.Journal of pathology informatics · 2026Article
- Proteomic Stability and Ex Vivo Compatibility of a Processed Phospholipoproteic Secretome-Derived Formulation.Pharmaceutics · 2026Article
- Effects of Nonionizing Millimeter-Wave on Spheroid-like Irradiated Non-Small-Cell Lung Cancer (NSCLC) Cells.International journal of molecular sciences · 2026Article
- HyPIC-3D enables characterization of migratory cancer cell subpopulations in 3D hypoxic microenvironments.Cell reports methods · 2026Article
- Oxidative Stress, Genetic Factors and Behavioral Responses to Chemical Exposure: Insights into Cancer Development in Zebrafish (Danio Rerio).Biochemical genetics · 2026Review
- Mechanisms of Resistance and Synergy: The Role of Tumor Microenvironment in HER2-Low Breast Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Adipocyte-Derived Extracellular Vesicles Endow Melanoma Cells with Stem-like Traits via PGC-1α-Mediated Mitochondrial Reprogramming.Antioxidants (Basel, Switzerland) · 2026Article
- Three-dimensional culture of tumor cells (Review).Oncology letters · 2026Review
- Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer.NPJ precision oncology · 2026Article
- Diversity within ovarian cancer subtypes and their tumor microenvironment.Frontiers in oncology · 2026Review
- Oxidative stress as a nexus: Integrating mitophagy and ferroptosis in endometrial carcinogenesis (Review).Oncology letters · 2026Review
- Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.Frontiers in cell and developmental biology · 2026Review
- Plying potency assays for immunotherapy of solid tumors.Frontiers in immunology · 2026Review
- Understanding the immunomodulatory mechanisms for natural products that overcome tumor chemoresistance to platinum-based cancer drugs and other treatments.Frontiers in pharmacology · 2026Review
- Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges.Frontiers in pharmacology · 2026Review
- JMJD5: a multifunctional regulator in development, homeostasis, and cancer.Frontiers in cell and developmental biology · 2026Review
- A mechanobiology-driven cell-derived ECM bioink for engineering 3D glioblastoma tumor microenvironment models.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is increasingly appreciated to play a decisive role in cancer development and response to therapy in all solid tumors. Hypoxia, acidosis, high interstitial pressure, nutrient-poor conditions, and high cellular heterogeneity of the TME arise from interactions between cancer cells and their environment. These properties, in turn, play key roles in the aggressiveness and therapy resistance of the disease, through complex reciprocal interactions between the cancer cell genotype and phenotype, and the physicochemical and cellular environment. Understanding this complexity requires the combination of sophisticated cancer models and high-resolution analysis tools. Models must allow both control and analysis of cellular and acellular TME properties, and analyses must be able to capture the complexity at high depth and spatial resolution. Here, we review the advantages and limitations of key models and methods in order to guide further TME research and outline future challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.